Biologics · COPD & Asthma
Xolair Assistance Programs & Grants in Utah
Assistance information last verified: August 2026
Yes, and through a route most manufacturer programs do not offer. The Genentech Patient Foundation covers Xolair and lets people who already have insurance qualify if their plan's out-of-pocket maximum exceeds 7.5% of their yearly income — which is how a Medicare beneficiary gets in. Its income limits are flat dollar figures, not percentages of the poverty level. Every applicable charitable fund was closed. Financial assistance may be available through charitable foundations, manufacturer programs, Medicare's Extra Help program, or other assistance resources. Availability and eligibility change frequently — the information on this page was verified in August 2026.
Can I get help paying for Xolair?
Yes, and through a route most manufacturer programs do not offer. The Genentech Patient Foundation covers Xolair and lets people who already have insurance qualify if their plan's out-of-pocket maximum exceeds 7.5% of their yearly income — which is how a Medicare beneficiary gets in. Its income limits are flat dollar figures, not percentages of the poverty level. Every applicable charitable fund was closed.
- Genentech Patient Foundation: Xolair is a participating medicine. Three qualifying routes, and the third is the one for insured people — "the out-of-pocket maximum set by my health insurance plan is more than 7.5% of my yearly income."
- Income limits are flat dollars: under $75,000 for one person, under $100,000 for two, under $125,000 for three, under $150,000 for four, adding $25,000 per additional person. No FPL percentage is involved.
- Part B or Part D? CMS lists Xolair with HCPCS J2357, a Part B code, but the label also supports self-injection at home. Establish which benefit pays before you plan — Extra Help only helps on the Part D side.
- Medicare negotiation: Xolair is a SELECTED drug for initial price applicability year 2028. No negotiated price has been published yet.
- Charitable grants: TotalAssist lists Xolair on its Asthma fund ($1,200/$3,500) AND its Chronic spontaneous urticaria fund ($2,600/$5,200) — all closed. If you have CSU, that is the larger award and the one to set an alert on.
- No generic and no biosimilar: DailyMed labels exactly one omalizumab product.
1 of the 4 programs we checked for Xolair was accepting applications when verified in August 2026.
About Xolair (omalizumab)
Xolair is an injected biologic — the label calls it "an anti-IgE antibody" — that blocks immunoglobulin E, the antibody behind allergic reactions. It is unusual among the medications on this site for treating four quite different conditions, and that matters practically: the charitable fund you qualify for, and the size of its award, depend on which of them you were prescribed it for.
Approved uses
- Moderate to severe persistent asthma in adults and children aged 6 and over with a positive allergy test and symptoms not controlled by inhaled corticosteroids
- Chronic rhinosinusitis with nasal polyps in adults, as add-on maintenance treatment when nasal corticosteroids have not worked well enough
- IgE-mediated food allergy in adults and children aged 1 and over, to reduce allergic reactions including anaphylaxis after accidental exposure — used alongside food allergen avoidance, not instead of it
- Chronic spontaneous urticaria (long-lasting hives with no identified cause) in people aged 12 and over who remain symptomatic despite antihistamines
Manufacturer: Genentech
Why Xolair can be expensive on Medicare
Xolair is a brand-only biologic with no generic and no biosimilar — DailyMed labels exactly one omalizumab product. Doses are weight- and IgE-based, so two people on Xolair can be prescribed very different quantities, and the cost follows. Where the drug lands on your Medicare coverage adds a second variable: the CMS negotiation file lists Xolair with a Part B billing code, while the label also supports self-injection at home with a prefilled syringe or autoinjector. Part B and Part D share costs differently, so the same medicine can produce quite different bills depending on how you receive it.
Medicare coverage context
Xolair can reach you through either Medicare benefit, and this is the first thing to establish. If you self-inject at home with a prefilled syringe or autoinjector, it is normally a Part D or Medicare Advantage drug-plan matter, generally on a specialty tier with prior authorization. If it is administered in a clinic or infusion setting, it may be billed under Part B — CMS's own negotiation file lists Xolair with HCPCS code J2357, which is a Part B code. That distinction changes your cost-sharing, and it changes which help applies: Extra Help is a Part D subsidy and does nothing for a Part B coinsurance, whereas a Medigap policy or a Medicare Savings Program can. Ask your prescriber's office which benefit your doses run through before planning around a figure. Xolair is also one of the 15 drugs CMS selected for the third negotiation cycle, with any negotiated price effective January 1, 2028; no price has been published yet.
Check typical Part D coverage · Estimate your drug costs · Compare Part D plans in Vernal
Xolair assistance options at a glance
Every program we checked, what kind of help it is, whether people with Medicare can use it, and its status when we verified it. A medication being listed by a program is not the same as the program accepting applications.
About the income limits below: Income limits can differ between assistance programs even when both describe their eligibility as the same percentage of the federal poverty level. The dollar limits shown here come from each program's own published income table, and each program decides which year's poverty guidelines that table is built from and when it takes effect. Treat the figures as belonging to the program they are listed under — they are not interchangeable, and only the program can tell you which table it is applying to your application today.
| Program | Type of help | People with Medicare | Status (August 2026) |
|---|---|---|---|
| Genentech Patient Foundation | Manufacturer patient assistance | with conditions | Accepting applications |
| TotalAssist — Asthma and Chronic spontaneous urticaria funds | Charitable grant | may apply | Closed to new applicants |
| HealthWell Foundation — Asthma and Urticaria funds | Charitable grant | may apply | Closed to new applicants |
| Good Days — no applicable fund | Charitable grant | not stated | No program found |
| Medicare Extra Help (Part D Low-Income Subsidy) | Government program | may apply | Accepting applications |
Manufacturer programs from Genentech
A patient assistance program (free or low-cost drug by income) is not the same as a copay card (a commercial discount that usually excludes Medicare). Both are listed so you can see which one applies to you.
Manufacturer patient assistance
Genentech Patient Foundation
Genentech
Status: Accepting applications on August 26, 2026. Xolair is one of 36 participating medicines. Genentech states it "reserves the right to modify or discontinue the program at any time and to verify the accuracy of information submitted".
A genuine free-medicine program covering Xolair, and the only one in this registry with an out-of-pocket-maximum test rather than a pure income test. That design is what makes it reachable for people whose income is ordinary but whose specialty-drug cost-sharing is not.
If you have Medicare: Medicare beneficiaries can qualify, and the route is unusual enough to be worth reading twice. Genentech does not ask whether you have Medicare; it asks which of three situations you are in. The third — "I have insurance that covers my Genentech medicine, but the out-of-pocket maximum set by my health insurance plan is more than 7.5% of my yearly income" — is written for insured people, and a Part D specialty tier or a Part B coinsurance on a biologic will often clear that bar. Work out your plan's out-of-pocket maximum and 7.5% of your gross yearly income before you call, because that comparison is the whole test. Note also that Genentech uses flat dollar income limits rather than a percentage of the federal poverty level, so the figures here are not comparable with the FPL-based limits other programs on this site publish.
What it can cover: Free Genentech medicine, including Xolair, for people who meet one of the three qualifying situations and the income limits.
Who may qualify
- You are in one of three situations: you have no insurance; you have insurance but it does not cover your Genentech medicine; or you have insurance that covers it but your plan's out-of-pocket maximum is more than 7.5% of your yearly income
- Total yearly income under $75,000 for one person, $100,000 for two, $125,000 for three, or $150,000 for four
- For households of more than four, add $25,000 to the income limit for each additional person
- Genentech describes the program as inclusive "no matter their race, citizenship/immigration status, age, disability, gender identity or sexual orientation"
What the application asks for
- Proof of your total yearly household income
- Your insurance details, including your plan's out-of-pocket maximum if you are applying under the 7.5% route
- Your prescriber's details and prescription information
How to apply
Call a Foundation Specialist on (888) 941-3331 (Monday–Friday, 6am–5pm PT) — Genentech offers support in many languages — or start from the Patient Foundation pages. Applications can also be faxed to (833) 999-4363. Have your plan's out-of-pocket maximum and your yearly income to hand, because the 7.5% comparison is what decides an insured applicant's eligibility.
Charitable grants for Xolair
Xolair's charitable picture is shaped by its four indications, and it pays to know which one is yours. TotalAssist covers it on the Asthma fund ($1,200 guaranteed, $3,500 maximum), on the Asthma health equity fund at the same level, and on the Chronic spontaneous urticaria fund at $2,600 guaranteed and $5,200 maximum — more than double, for the same medicine. HealthWell mirrors this with an Asthma fund and a Urticaria fund. Every one of those funds was closed on August 26, 2026, and Good Days has none. Two indications — nasal polyps and IgE-mediated food allergy — have no charitable fund on any of the three foundations, which is a real gap rather than an oversight in our checking. So: set your alert on the fund that matches your diagnosis, not the first one you find, and treat the Genentech Patient Foundation as the primary route, because its 7.5% out-of-pocket test does not depend on a fund balance.
Charitable grant
TotalAssist — Asthma and Chronic spontaneous urticaria funds
Patient Advocate Foundation · Asthma · Asthma health equity · Chronic spontaneous urticaria (CSU)
Status: All three applicable funds were closed to new applicants on August 26, 2026. The awards differ substantially: the Asthma funds pay $1,200 guaranteed up to $3,500, while the CSU fund pays $2,600 guaranteed up to $5,200 — for the same medication.
The most useful thing to know here is that Xolair sits on two different funds with two different award sizes, and which one applies depends on your diagnosis rather than your prescription. If you were prescribed Xolair for chronic spontaneous urticaria, the CSU fund is worth more than twice the asthma fund. Both were closed when we checked, so set alerts on the right one.
If you have Medicare: These funds require government-insured coverage — Medicare, Medicaid or TRICARE — that covers your qualifying expenses. Medicare beneficiaries are eligible when a fund is open. Note that a fund pays toward what your insurance leaves you, so if your Xolair runs through Part B rather than Part D, say so on the application.
What it can cover: When open: for asthma, $1,200 guaranteed and up to $3,500 maximum; for chronic spontaneous urticaria, $2,600 guaranteed and up to $5,200 maximum. Covers medication copays, coinsurance, deductibles and health-insurance premiums. One grant per condition.
Who may qualify
- A confirmed diagnosis matching the fund — asthma, or chronic spontaneous urticaria — in treatment, starting within 60 days, or treated in the past 6 months
- Government-insured coverage (Medicare, Medicaid or TRICARE) that covers your qualifying expenses
- Household income at or below 500% of the federal poverty level, adjusted for your regional cost-of-living index
- Confirmed diagnosis matching the fund, and in treatment (or starting within 60 days, or treated in the past 6 months)
- Legal U.S. resident receiving treatment in the U.S. or a U.S. territory
- The asthma health-equity fund additionally requires a home zip code in a designated social-vulnerability county
What the application asks for
- Contact information and Social Security number (or alien number)
- Annual household income (for pre-screening; proof of income due within 30 days of approval)
- Health insurance carrier, plan type, policy ID and group number; Medicare supplement or secondary insurance if you have one
- Copay or coinsurance amounts
- Your provider's name and contact information, diagnosis (exact date if within 6 months), prescribed medications and treatment plan
How to apply
Sign up for fund notifications (text, email or automated call) at totalassist.org/notify — and sign up for the fund matching your diagnosis, since the awards differ. When a fund opens: You (the patient) apply online — it takes about 15 minutes and you learn immediately whether you are approved — or call 866-512-3861, Monday–Friday 8:30am–5:30pm ET. Patient Advocate Foundation verifies your diagnosis and treatment plan directly with your provider and verifies income automatically; you have 30 days after approval to provide proof of income.
Charitable grant
HealthWell Foundation — Asthma and Urticaria funds
HealthWell Foundation · Asthma · Urticaria
Status: Both funds that could cover Xolair were closed on August 26, 2026. HealthWell runs no fund for nasal polyps and none for food allergy, so two of Xolair's four indications have no HealthWell route at all.
HealthWell mirrors the TotalAssist picture — a fund for asthma and a fund for urticaria, both closed. Worth setting alerts on both if your diagnosis could match either, since HealthWell reopens funds as money is replenished.
If you have Medicare: HealthWell accepts Medicare beneficiaries for the diseases it covers. Its Asthma and Urticaria funds are the two that could apply to Xolair; neither was open when we checked.
What it can cover: When open: copays, coinsurance, deductibles and health-insurance premiums for the covered diagnosis.
Who may qualify
- A confirmed asthma or urticaria diagnosis, verified by your prescriber
- Some form of health insurance (Medicare qualifies) that covers part of the cost of the drug — discount cards do not count
- Social Security number (used to prevent duplicate applications)
- Diagnosis verified by a physician's, nurse practitioner's or physician assistant's signature
- Treatment in the United States
What the application asks for
- Some form of health insurance (Medicare qualifies) that covers part of the cost of the drug — discount cards do not count
- Social Security number (used to prevent duplicate applications)
- Diagnosis verified by a physician's, nurse practitioner's or physician assistant's signature
- Treatment in the United States
How to apply
When a fund is open, apply online or by phone; your provider verifies the diagnosis by signature. When a fund is closed, sign up for that fund's real-time alerts — HealthWell says replenished funds reopen "as quickly as possible."
Charitable grant
Good Days — no applicable fund
Good Days
Status: Good Days' published disease list on August 26, 2026 contained 57 programs and none matched any of Xolair's four indications — no asthma, urticaria, nasal polyp or food-allergy program.
An honest negative, checked so you do not spend time on a third foundation that has no fund for you.
If you have Medicare: Good Days accepts Medicare beneficiaries for the diseases it covers, but it covers no diagnosis that applies to Xolair.
How to apply
Not applicable today. The diseases-covered page shows every fund Good Days runs.
How to apply for Xolair assistance
The written steps are complete on their own; the video above will walk through the same process when it is published.
-
Step 1 — Find the applicable assistance program
For Xolair on Medicare in August 2026, two questions come before any application: which benefit pays, and which diagnosis you were prescribed it for.
- Ask your prescriber's office whether your doses are billed under Part B or Part D. It changes your cost-sharing and which help applies.
- Work out whether your plan's out-of-pocket maximum exceeds 7.5% of your yearly income — if it does, apply to the Genentech Patient Foundation.
- Limited income and resources, and Part D coverage → Medicare Extra Help through Social Security.
- Chronic spontaneous urticaria → set an alert on the TotalAssist CSU fund, which pays more than double the asthma fund.
- Asthma → set alerts on the TotalAssist and HealthWell asthma funds (all closed when checked).
- Part B coverage with high coinsurance → look at Medigap and Medicare Savings Programs rather than Extra Help.
-
Step 2 — Check whether applications are currently open
The manufacturer foundation was open; every charitable fund was closed.
- Genentech Patient Foundation: open on the checked date. Genentech reserves the right to modify or discontinue the program at any time.
- TotalAssist: the Asthma and Chronic spontaneous urticaria fund pages each show "Open" or "Closed" and their own award amounts.
- HealthWell: the disease-funds list shows the Asthma and Urticaria funds and their status.
-
Step 3 — Check eligibility
Genentech's test is different from every other program on this site, so read it carefully:
- Genentech Patient Foundation: you must be in one of three situations — no insurance; insurance that does not cover Xolair; or insurance that does cover it but with an out-of-pocket maximum above 7.5% of your yearly income. Income under $75,000 for one person, $100,000 for two, $125,000 for three, $150,000 for four, plus $25,000 per additional person.
- These are flat dollar limits, not percentages of the federal poverty level, so do not compare them with the FPL figures other programs publish.
- TotalAssist (when open): government insurance covering Xolair; income at or below 500% FPL adjusted for your regional cost-of-living index; a confirmed diagnosis matching the specific fund.
- HealthWell (when open): insurance that covers part of the drug's cost, a prescriber-verified diagnosis, and treatment in the United States.
- Extra Help: income below about $23,940 a year for one person or $32,460 for a couple, and countable resources limited to $18,090 or $36,100 in 2026 — and it only helps on the Part D side.
-
Step 4 — Gather your information
Two documents matter more here than on most pages:
- Your plan's out-of-pocket maximum, in dollars. This is the number Genentech compares against 7.5% of your yearly income, and it is on your plan documents rather than your card.
- Your total yearly household income and household size.
- Which of Xolair's indications you were prescribed it for — asthma, nasal polyps, food allergy or chronic spontaneous urticaria. The charitable funds and their award sizes differ by diagnosis.
- Whether your doses are self-injected at home or given in a clinic, and which Medicare benefit is billed.
- Medicare card, drug-plan card, and your prescriber's name, office and phone.
-
Step 5 — Complete the application
Who fills out what:
- Genentech Patient Foundation: call (888) 941-3331 and a Foundation Specialist will work through it with you; support is offered in many languages. Applications can also be faxed to (833) 999-4363.
- Extra Help: you (or someone helping you) apply free through Social Security — online, by phone on 1-800-772-1213, or at an office. There is never a fee.
- TotalAssist (when open): you apply online in about 15 minutes or by phone on 866-512-3861; apply to the fund matching your diagnosis.
- HealthWell (when open): apply online or by phone; your provider verifies the diagnosis by signature.
-
Step 6 — Submit and wait for a determination
What to expect:
- Genentech Patient Foundation: the foundation verifies the information you submit; a Foundation Specialist can tell you the current timeframe when you call.
- Extra Help: Social Security notifies you by mail; your Part D plan then applies the lower copays.
- TotalAssist (when open): an immediate online decision, with proof of income due within 30 days of approval.
- HealthWell (when open): a decision once your provider returns the diagnosis verification.
-
Step 7 — If the program is closed or you don't qualify
For a biologic with no generic, the structural fixes matter more than shopping around:
- Re-run the Genentech 7.5% test carefully before accepting a no — people often compare against take-home pay rather than yearly income, or use their deductible rather than their out-of-pocket maximum.
- Ask whether your doses could be administered in a different setting, and what that would do to your share. The Part B / Part D difference is the largest single lever on this medication.
- If you are on Part B, look at Medigap and Medicare Savings Programs — these are the tools that reduce a Part B coinsurance, and Extra Help is not.
- Enrol in the Medicare Prescription Payment Plan if Xolair runs through Part D; it spreads the cost across the year rather than lowering it.
- Do not wait for a generic — DailyMed labels exactly one omalizumab product, and no biosimilar exists.
- Watch for the Medicare negotiated price: Xolair is selected for 2028, though no price has been published yet.
- Call Vernal Medicare — we will work through every route above with you, free.
What you'll need
Only items the programs above actually ask for. Gather these before you start.
- Medicare card and your Part D or Medicare Advantage drug-plan card — plan name, member ID and group number
- Prescription details — medication name, strength and dose; prescriber name, office phone and address
- Diagnosis and date of diagnosis — TotalAssist needs the exact date if diagnosed within the past 6 months
- Household size and annual household income — and proof — tax return, Social Security or pension statements, or pay stubs
- Your plan's annual out-of-pocket maximum, in dollars — the Genentech Patient Foundation compares this against 7.5% of your yearly income — it is the deciding number for insured applicants
- Which of Xolair's four indications you were prescribed it for — the TotalAssist CSU fund pays $2,600/$5,200 while the asthma funds pay $1,200/$3,500
- Whether your doses are self-injected at home or given in a clinic — this decides whether Part B or Part D pays, and therefore which assistance applies
Could Medicare Extra Help reduce your Xolair costs?
Extra Help is not a grant for Xolair. It is a Medicare program that lowers what qualifying beneficiaries pay for their Part D premium, deductible and every covered prescription — so it is worth checking even when a charitable fund is closed, because it does not depend on fund balances.
Extra Help is worth applying for, but be clear about what it can and cannot do for this medication. Extra Help is a Part D subsidy: if you self-inject Xolair at home and it runs through your drug plan, it lowers your cost-sharing, and with full Extra Help a covered brand-name drug costs about $12.65 in 2026. If your Xolair is administered in a clinic and billed under Part B, Extra Help does not touch that coinsurance — a Medigap policy or a Medicare Savings Program is the tool for the Part B side. Find out which benefit pays for your doses first; it determines which of these is worth your time. Note also that Genentech's program does not exclude Extra Help enrollees, so holding both is possible.
In 2026, people with full Extra Help generally pay no more than $12.65 for a covered brand-name drug. Income must be below about $23,940 a year for one person ($32,460 for a couple) and countable resources under $18,090 ($36,100 for a couple). Apply free through Social Security — online, by phone at 1-800-772-1213, or in person — and never pay anyone to apply for you.
Extra Help explained (Utah) · Check if you might qualify · Medicare Savings Programs · All help paying for Medicare
Government program
Medicare Extra Help (Part D Low-Income Subsidy)
Medicare / Social Security Administration
Status: Year-round federal program (figures for 2026)
Not a grant for one drug — a Medicare program that lowers what qualifying beneficiaries pay for their Part D premium, deductible and every covered prescription.
If you have Medicare: For people with Medicare Part D or a Medicare Advantage drug plan who have limited income and resources.
What it can cover: Part D premium and deductible (often to $0) and reduced copays — generally no more than $12.65 for a covered brand-name drug in 2026 with full Extra Help.
Who may qualify
- Income below 150% of the federal poverty level — about $23,940 a year for one person or $32,460 for a married couple in 2026.
- Countable resources (savings, investments — not your home or car) limited to $18,090 for an individual or $36,100 for a married couple living together in 2026 (Medicare.gov figures, which include a burial-expense allowance).
- Automatic if you have Medicaid, Supplemental Security Income (SSI), or a Medicare Savings Program.
What the application asks for
- Social Security number and Medicare number
- Income (Social Security, pensions, wages) for you and a spouse you live with
- Value of savings, investments and other countable resources
How to apply
You (or someone helping you) apply free through Social Security — online, by phone, or at a Social Security office. There is never a fee to apply.
Key terms on this page
- Patient assistance program (PAP)
- A manufacturer program that provides its medication free or at low cost to people who meet income and insurance rules. Many PAPs accept Medicare Part D enrollees; each sets its own criteria.
- Copay card / savings card
- A manufacturer discount for commercially insured patients. Federal anti-kickback rules mean these cards generally cannot be used with Medicare, Medicaid or other government insurance.
- Charitable copay grant
- Money from a nonprofit foundation (for example HealthWell or Patient Advocate Foundation) that pays eligible copays or coinsurance for a specific diagnosis. A drug can be listed while the fund is closed to new applicants.
- Federal poverty level (FPL)
- A federal income measure that assistance programs use as a yardstick — "300% of FPL", "500% of FPL". The percentage is a rule, but the dollar figure behind it comes from a table each program publishes itself, built on a chosen year of the HHS poverty guidelines. Two programs can quote the same percentage in the same year and still list different dollar limits; compare each program against its own table, not against another program.
- Medicare Extra Help
- The Part D Low-Income Subsidy: a Medicare program that lowers or eliminates Part D premiums, deductibles and copays for beneficiaries with limited income and resources. You apply through Social Security.
- Maximum Fair Price (MFP)
- The price Medicare negotiated for a selected drug under the Medicare Drug Price Negotiation Program. It applies to Part D plans, not to the pharmacy cash price, and it lowers what plans and enrollees pay for that drug.
Related medication assistance guides
Frequently Asked Questions
Does Medicare cover Xolair?
How can I qualify for the Genentech Patient Foundation if I already have Medicare?
Why does the charity award for Xolair differ so much between funds?
Is Xolair part of Medicare drug price negotiation?
Is there a generic or biosimilar for Xolair?
Is there a charitable grant for Xolair right now?
Sources
- Xolair prescribing information (DailyMed) — U.S. National Library of Medicine (2026-08-26)
- DailyMed label index — omalizumab — U.S. National Library of Medicine (2026-08-26)
- Genentech Patient Foundation — overview and eligibility — Genentech (2026-08-26)
- Genentech Patient Foundation — eligibility criteria (Overview brochure) — Genentech (2026-08-26)
- Genentech Patient Foundation — our participating medicines — Genentech (2026-08-26)
- TotalAssist — Asthma fund — Patient Advocate Foundation (2026-08-26)
- TotalAssist — Chronic spontaneous urticaria (CSU) fund — Patient Advocate Foundation (2026-08-26)
- TotalAssist — Asthma health equity fund — Patient Advocate Foundation (2026-08-26)
- Get notified when a fund opens — TotalAssist — Patient Advocate Foundation (2026-08-26)
- TotalAssist eligibility requirements — Patient Advocate Foundation (2026-08-26)
- HealthWell disease funds (full list) — HealthWell Foundation (2026-08-26)
- HealthWell disease funds (status list) — HealthWell Foundation (2026-08-26)
- Good Days — diseases covered — Good Days (2026-08-26)
- Selected Drug List and Negotiated Prices (Maximum Fair Prices) data file — CMS (2026-08-26)
- Selected Drug List for Initial Price Applicability Year 2028 (fact sheet) — CMS (2026-08-26)
- Your Medicare in 2026: what you need to know — Medicare.gov (2026-08-26)
- Help with drug costs (Extra Help) — Medicare.gov (2026-08-26)
- Medicare Prescription Payment Plan — Medicare.gov (2026-08-26)
- Special Advisory Bulletin: Pharmaceutical Manufacturer Copayment Coupons — HHS Office of Inspector General (2026-08-26)
Having trouble figuring out your prescription costs?
If you live in Vernal or the Uintah Basin, Vernal Medicare can help you understand your Medicare prescription coverage and where to look for Xolair assistance — free, no pressure. We don't award grants or decide eligibility; the programs above do. We help you find and apply to the right ones.